Thus, it becomes crucial to consider and further elucidate the, at least partially, ambiguous and target cell-specific role of CXCR3 signaling [36,40] when discussing this chemokine receptor and its ligands as potential targets for CRC immunotherapy. This evidence concerns the gene CXCR3 and colorectal carcinoma.